Dyax Corp. (NASDAQ:DYAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Recs

1
Player Avatar beefsteakfarmer (30.19) Submitted: 3/13/2007 10:42:54 AM : Outperform Start Price: $3.95 DYAX Score: +106.85

The immediate future may not be encouraging but the long term will outperform the s&p. Look for the place to get in and then exit when the dx-88 sends the stock soaring for a little while.

Featured Broker Partners


Advertisement